Abstract
In stark contrast to the rest of the pharmaceutical industry, the world market for biotech drugs is thriving. In 2005, biotech revenues reached $60bn and visiongain predicts that this will continue - YOU MUST BE PART OF THIS SUCCESS NOW. Order a copy of visiongain' s new report to get the details.
Having grown 16.5 per cent from 2004' s revenues, double-digit growth of the market will continue to the end of the decade. You need to be aware of how you can succeed in this area. 1 report will tell you all you need to know. SO order this report NOW.
- Over 250+ pages
- Over 150 tables and figures
- Global revenues & growth rates for the leading biotech drugs
- Company profiles of the leading biotech firms
- A comprehensive analysis of the global market, 2005-2011
- Revenue forecasts for the leading biotech drugs
- Revenues into therapeutic area
- Pipeline treatments
- A geographic breakdown of the market
- A Focus on biogenerics
Designed as an essential business aid, The Global Biotech Report 2006 provides the leading thorough evaluation of your market.
The report provides you with in-depth market analysis for all top-selling current and major potential products to arrive before the decade ends. The report extensively identifies biopharmaceuticals market potential by analysing the latest clinical trial research. The study also examines the challenges faced by potential biotech companies and opportunities newcomers to the arena. This is the industry' s premier report. Numbers are strictly limited, so order today.
Five key questions this report answer' s are:
- 1. What are the market values of the major therapeutic areas of the global biopharmaceutical market by product from, 2005 to 2011?
- 2. Who are the major companies involved in the world market today and in the future, and will they be competition to you?
- 3. How imminent are biogenerics and what is their potential market value?
- 4. What strategies can be used to maximise your profits in terms of the major challenges facing biotech?
- 5. What' s in the 2006 biopharmaceutical pipeline and what revenues can they reach by 2011?
Due to visiongain' s targeted consultancy work in the area, only a strict 20 copies of the report are issued. Please order your copy now so as you do not miss out. Copies will be reserved on a strictly first-come-first-serve basis. So please contact us now.
This report is a vital addition to gaining an understanding of this highly profitable market sector and will give your company ' the edge' of your competitors. You can not afford to be without this report from visiongain.
Table of Contents
Chapter 1: Executive Summary of World Biotech Market, 2006
- 1.1 Abstract of Biotech, 2006
- 1.2 Aims, Scope and Format of Biotech, 2006
Chapter 2: Introduction to Biotechnology
- 2.1 What is Biotechnology?
- 2.2 The Uniqueness of Biopharmaceuticals: Turning Medicine Around
- 2.3 Biotechnologies Used and Their Applications to Pharma
- 2.3.1 Bioprocessing Technology
- 2.3.2 Monoclonal Antibodies
- 2.3.3 Recombinant DNA Technology
- 2.3.4 Cloning
- 2.3.4.1 Molecular Cloning
- 2.3.4.2 Cellular Cloning
- 2.3.4.3 Animal Cloning
- 2.3.4.4 Protein Engineering
- 2.4 The Future Biopharmaceutical Market
- 2.4.1 Biopharmaceutical 2004 Market Capitalisation Worth $311bn
- 2.4.2 Over 7000 Biotechnology Patents Granted Per Annum Since 1998
- 2.4.3 2004 Witnessed 54 New Biopharmaceuticals Approved by the FDA
- 2.4.4 Biopharmaceuticals Share 12.5% of 2004 Global Prescriptions
Chapter 3: Diseases Treated by Biopharmaceuticals
- 3.1 Biopharmaceuticals Are Versatile Agents
- 3.2 Orphan Diseases Are A Major Target of Biotech: 3 Out of 10 2004 Orphan Disease Drug Approvals Were Biopharmaceuticals
- 3.3 Overview of Major and Orphan Diseases Treated By Biopharmaceuticals, 2005
Chapter 4: Overview of Biopharmaceuticals Market, 2004-2005
- 4.1 Monoclonal Antibodies: Leading Class of Biopharmaceuticals in 2005 With Sales of $20bn
- 4.2 Biopharmaceuticals by Therapy Class: Blood Disorders Share Over A Quarter of the 2004 Biopharmaceuticals Market
- 4.3 2005 Biopharmaceuticals Market Worth a Staggering $59.5bn
- 4.4 The Top 20 Selling Biopharma Drugs of 2005 Accounted For 69% of Total Revenues
- 4.5 The Top 3 Biopharmaceuticals Products of 2005 Sold Over $17bn
- 4.5.1 MAbs Lead the Market
- 4.5.2 Procrit/Eprex - 2004' s Number One Biologic - Loses Top Spot in 2005
Chapter 5: Biotech Company Revenues and Market Share, 2005
- 5.1 Amgen: The Reign Continues With A 17% Share of 2005 Market
- 5.1.1 Who Are Amgen?
- 5.2 The Strong Partnership Flourishes Between Roche and Genentech
- 5.3 Collaborative Projects Grew by 30%
- 5.4 Biotech Company Winners and Losers in 2005
Chapter 6: Biopharmaceutical Pipeline
- 6.1 Technology Driving Biopharma Pipeline
- 6.2 Biotech Targeting Chronic Illness
- 6.3 Arthritis Biopharmaceutical Pipeline, 2006
- 6.4 MS Biopharmaceutical Pipeline, 2006
- 6.5 Late-Stage Biopharmaceutical Oncology Pipeline, 2006
- 6.6 Late Stage Biopharmaceutical Vaccine Pipeline, 2006
- 6.7 Blood Disorders Biopharmaceutical Pipeline, 2006
- 6.8 Late Stage Biopharmaceutical Endocrine Pipeline, 2006
- 6.9 Anti-Infectives Biopharmaceutical Pipeline, 2006 6.10 Enzyme Deficency Biopharmaceutical Pipeline, 2006
- 6.11 Late Stage Biopharmaceutical Opthalmic Pipeline, 2006
- 6.12 Late Stage Biopharmaceutical ' Other' Pipeline, 2006
Chapter 7: Biopharmaceutical Market Forecast by Therapeutic Area, 2005-2011
- 7.1 Blood Disorders
- 7.2 Endocrine Disorders
- 7.3 Multiple Sclerosis
- 7.4 Oncology
- 7.5 Hepatitis Treatments (inferon alpha)
- 7.6 Enzyme Deficiency Disorders
- 7.7 Vaccines
- 7.8 Arthritis
- 7.9 Others
- 7.10 Biopharmaceutical Market Set To Almost Double by 2011
Chapter 8: Summary of the 2011 Biopharmaceuticals Market
- 8.1 Enbrel Will Continue to Lead the World Biotech Market
- 8.2 Blood Disorders Will Remain Market Leaders
Chapter 9: Introduction to Biogenerics
- 9.1 The Emergence of Biogenerics
- 9.1.1 Patent Expiry for Key Biotech Drugs
- 9.1.2 Names are Important
- 9.2 Improved Technology Has Strengthened the Case for Biogenerics
- 9.3 Bioequivalence Will Remain Difficult to Demonstrate
Chapter 10: The Potential Biogeneric Market
- 10.1 $11bn of Biopharmaceuticals To Lose Patent Protection By 2007
- 10.2 High-Revenue Generating Biopharmaceuticals Face Patent Expiry
- 10.3 Erythropoetins are the Most Attractive Target for Biogenerics
- 10.4.1 The Regulatory Authorities Will Require Extensive Data for EPO
- 10.4 Interferons are Going to Face High Competition from Biogenerics
Chapter 11: Biopharmaceutical Market Challenges
- 11.1 BioTech' s Delivery Challenge
- 11.1.1 Pulmonary Delivery: An Innovative Alternative to the Needle?
- 11.1.2 The Major Issues of the Pulmonary Pathway
- 11.1.3 Does Protein Formulation Affect Pulmonary Delivery?
- 11.1.4 Does Pulmonary Drug Delivery Have a Future?
- 11.1.5 Pegylated Forms Set to Revolutionise Delivery
- 11.1.6 Pegylation Can Extend Patent Protection - The Case of Filgrastim
- 11.1.7 Transdermal Technologies
- 11.1.8 Microneedles for Transdermal Delivery of Vaccines
- 11.1.9 Nasal Delivery Is Demonstrating Promise 11.1.10 Moving Towards Pills - Altus' Unique Technology
- 11.1.11 New Delivery Technologies: A Pharmacy or Medical Benefit?
- 11.1.12 Innovative Insulin Delivery Technology: The Race is On
- 11.1.13 Numerous Potential Blockbusting NonInjected Insulins Set to Arrive 2005-2009
- 11.2 Manufacturing Capacity Shortfall
- 11.2.1 Why is There a Shortfall in Manufacturing Capacity for Biopharmaceuticals?
- 11.2.2 Make Vs. Buy: The 1980s BioIndustry
- 11.2.3 CMO Manufacturing Capacity was Adequate for the Supply of Clinical Materials Only
- 11.2.4 Late-Stage Products have absorbed CMO Clinical Manufacturing Capacity
- 11.2.5 How is the Manufacturing Capacity Shortfall Being Overcome?
- 11.2.6 Does The Future for Biopharmaceutical Manufacturing Lie with Transgenics?
- 11.3 The Cost of Biopharmaceutical
- 11.3.1 The Top Five Biopharmaceuticals Each Cost at Least $10K Per Patient Per Annum
- 11.3.2 Monoclonal Antibodies and CSF' s High Costs Reflect Production Difficulties
- 11.3.3 Yeast-Based Systems May Bring Down the Cost of Therapeutic Proteins in the Future
- 11.4 Acquiring Capital
- 11.4.1 Financing of Biotech Companies in 2003 Approached $17bn
- 11.5 Reliance Upon University/Company Collaborations
- 11.5.1 The Need For Collaboration
- 11.5.2 Biotech' s Increasing Role of Commercialising University Research
- 11.5.3 Future Biotech Innovation Lies With Academia
- 11.5.4 The Risky Path from Bench to Market
- 11.5.5 Collaboration Strategies & Becoming the Partner of Choice
- 11.5.5.1 Objectives That Support Strategic Goals
- 11.5.5.2 Understanding the Value Brought to an Alliance
- 11.5.5.3 Identifying and Understanding Potential Partners
- 11.5.5.4 Due Diligence
- 11.5.5.5 Promoting Capabilities to Potential Partners
- 11.5.5.6 Maintaining a Relationship Through Structured Interactions
- 11.5.5.7 Gaining Competitive Advantage
- 11.5.5.8 Collaboration Management: Developing and Maintaining A Deal
- 11.5.5.9 Strategic Goals to Consider
- 11.6 Regulatory Issues
- 11.6.1 Biopharmaceuticals and the FDA
- 11.6.2 FDA Improving Upon Biologics Approval Wait
- 11.7 Biogeneric Threat
- 11.8 Dependence upon Venture Capital Investment
- 11.9 Drivers and Restraints of Biopharmaceutical Market Growth
- 11.9.1 Drivers
- 11.9.2 Restraints
Chapter 12: Venture Capital Investment & Biotech
- 12.1 What is Venture Capital Investment?
- 12.2 What does VC Offer?
- 12.3 What Do Venture Capitalists Do?
- 12.4 Who Are Venture Capitalists?
- 12.4.1 Banks as Venture Capitalists
- 12.4.2 Business Angels (Wealthy Individuals) as Venture Capitalists
- 12.4.3 Corporate or Direct Investors as Venture Capitalists
- 12.4.4 Government Grants and Governments as Venture Capitalists
- 12.4.5 Venture Capital Firms
- 12.4.6 Other Types of Venture Capitalist
- 12.5 Why Do Biotech Companies Need VC Funding?
- 12.6 Venture Capital Investment in the US Biotech Market
- 12.6.1 US VC Investment Now Recovering Following Stockmarket Crash in 2000
- 12.6.2 329 US Biotech VC Investments Made in 2004, Providing Over $3.8bn
- 12.6.3 Synta Provides 2004' s Largest US Investment Sum With $80m
- 12.6.4 MPM Capital 2004' s Most Active US Biotech VC Firm
- 12.6.5 Company Expansion Stage is the Most Favourable for VC Investment
- 12.7 Increase in VC Funding of European Biotech
- 12.8 PE European Investments in Biotech Followed Similar Trends as in the US
- 12.9 European PE Biotech Investments are a Small part of the Funding Market
Chapter 13: The Global Biopharmaceutical Market by Country and Region,2004-2011
- 13.1 The World Biopharmaceutical Market is Dominated by the US
- 13.2 Both the Japanese and European Biotech World Market Share Set to Fall by 2011
- 13.3 The US Biotech Market Will Retain Its World Dominance
- 13.4 The European Biotech Market Will See Reduced Growth
- 13.5 European Biotech Industry Faces VC Funding Drop
- 13.6 Price Cuts in Japanese Biotech Market
- 13.7 Asia-Pacific Region: A Dormant Giant?
- 13.8 Biotech Industries in the Asia-Pacific Region are Growing Rapidly
- 13.9 China has the Most Biotech Companies in the Asia-Pacific region
- 13.10 Other World Markets
- 13.10.1 Russia Will See Growth in Biopharma Generics
- 13.10.2 Israel is and Area of Biotech Industry More than Market for Biotech Drugs
Chapter 14: The Human Genome Project and Its Influence on the Biotech Industry
- 14.1 Overall Project Goals
- 14.2 The Findings of the HGP:
- 14.2.1 Gene Numbers
- 14.2.2 Protein Coding
- 14.2.3 Nucleotide Sequencing
- 14.2.4 Gene Distribution
- 14.2.5 Variations and Mutations
- 14.3 Applications and Future Developments of the HGP
Chapter 15 - Conclusions: Biotech Comes of Age
- 15.1 Big Pharma Sees Biotech as an Opportunity
- 15.2 Biotech' s Major Challenges: Biogenerics and Budget Restraints
